CD33 and myelodysplastic syndrome: Fc-engineered monoclonal antibody against CD33 was demonstrated to improves the bone marrow microenvironment by reducing MDSC, blocking CD33 downstream signaling, preventing immune-suppressive cytokine secretion, and reducing both ROS and the levels of double stranded breaks and adducts in MDS [55] (Table 3).